TAYTON-MARTIN HELEN KATRINA 4

4 · Adaptimmune Therapeutics PLC · Filed Jan 17, 2023

Form 4

Period: 2023-01-17

Chief Operating Officer

Transactions

Award
Option to purchase Ordinary Shares
2023-01-17+314,256→ 314,256 total
Exercise: $0.00Exp: 2033-01-17→ Ordinary Shares (314,256 underlying)
Award
Option to purchase Ordinary Shares
2023-01-17+197,064→ 197,064 total
Exercise: $0.00From: 2024-01-17Exp: 2033-01-17→ Ordinary Shares (197,064 underlying)
Award
Option to purchase Ordinary Shares
2023-01-17+1,407,072→ 1,407,072 total
Exercise: $0.31Exp: 2033-01-17→ Ordinary Shares (1,407,072 underlying)

Footnotes (5)

[F1]The exercise price was converted from GBP0.26 based on an exchange rate of U.S. $1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.
[F2]Exercisable as to 351,768 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the seventeenth of each month from February 17, 2024 through December 17, 2026 and 29,454 Ordinary Shares on January 17, 2027.
[F3]The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.
[F4]Exercisable as to 78,564 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on January 17, 2025 and January 17, 2026, and 78,564 Ordinary Shares on January 17, 2027.
[F5]The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

Documents

1 file